Adaptimmune Therapeutics PLC · OTC:ADAPY
Adaptimmune Therapeutics — Investor Presentation (December 2015)
30 slides from Adaptimmune Therapeutics's investor presentation, Dec 15, 2015
Slide 1: Disclaimer
Disclaimer This presentation contains “forward-looking statements,” as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as “believe,” “may”, “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect” and o
Slide 2: Turning Promise into Products: Leading the TCR T-cell Therapy Space
Turning Promise into Products Leading the TCR T-cell Therapy Space A broad pipeline of clinical T-cell therapies to treat cancer First three programs target: NY-ESO First cohort in synovial sarcoma (solid tumor) shows 60% response rate at target dose First cohort in multiple myeloma (hematologic tum
Slide 3: A History of Scientific Pre-eminence
A History of Scientific Pre-eminence 1993-1999 Origins of TCR Technology 2005-2007 Original collaboration with Steven Rosenberg, MD, PhD 2008 Adaptimmune formed as virtual company with U Penn collaboration 2011 - Today Leadership position in: - Identifying targets - Generating T-cell receptors - Eng
Slide 4: Two Years of Delivery
Two Years of Delivery $104 million Series A Financing Cancer Immunotherapy collaboration Successful IPO raises $176 million Presentation of clinical data from multiple studies of NY-ESO therapy FDA acceptance of MAGE-A10 IND Updated data on NY-ESO therapy in synovial sarcoma and multiple myeloma Uni
Slide 5: Transformative Six Months Since IPO
Transformative Six Months Since IPO Rapidly Executing on the Promise of Immuno-oncology July: Publication of clinical and persistence data of NY-ESO in multiple myeloma September: Expansion of study of NY-ESO therapy in synovial sarcoma July: FDA acceptance of MAGE-A10 IND November: Updated data on
Slide 6: Positioned for Success: Experienced Management Team
Positioned for Success Experienced Management Team James Noble, MA, FCA Chief Executive Officer Helen Tayton-Martin, PhD MBA Chief Operating Officer Adrian Rawcliffe Chief Financial Officer Rafael Amado, MD Chief Medical Officer Gwen Binder-Scholl, PhD EVP, Adaptimmune LLC Head of Translational Scie
Slide 7: Enhancing T-Cell Receptors to Increase Tumor Specificity
Enhancing T-Cell Receptors to Increase Tumor Specificity The TCR is the natural mechanism for T-cells to distinguish a diseased cell from a healthy cell Many cancer targets are intracellular; TCR therapeutics can access them Adaptimmune enhances affinity to enable TCR to recognize cancer cells
Slide 8: The Leader in TCR T-cell Therapy: Four Key Components of Effective Delivery
The Leader in TCR T-cell Therapy Four Key Components of Effective Delivery The Right Affinity Safety Testing Proprietary Manufacturing The Right Targets T-Cell Expansion: CD3/CD28 Dynabeads® Multiple, soluble TCRs Potent and specific Enhanced TCRs Enhanced TCRs Clinical Candidate >30,000 peptides Mo
Slide 9: Uniquely Positioned for Success: Solving Development Hurdles
Uniquely Positioned for Success Solving Development Hurdles Low affinity of natural T-cells Safety evaluation of T-cell therapies Generating T-cell receptors (TCRs) Long term persistence and response Inability to target solid tumors Proprietary affinity optimization technology Proprietary preclinica
Slide 10: Uniquely Positioned for Success: Systematic Approach for Future Improvements
Uniquely Positioned for Success Systematic Approach for Future Improvements Other enhancements to activity Allogeneic T-cell therapies Second generation T-cell therapies Collaboration with Universal Cells Combination studies Beginning in 2016 Opportunities The Adaptimmune Solution Second generation
Slide 11: Uniquely Positioned for Success
Uniquely Positioned for Success Systematic Approach for Future Improvements Opportunities The Adaptimmune Solution Second generation T-cell therapies Second generation T-cell therapies Collaboration with Universal Cells, Beginning in 2016 Streamlining process; planning for automation Pilot plant und
Slide 12: TCR Targets Cover Broad Array of Solid and Hematologic Tumors
TCR Targets Cover Broad Array of Solid and Hematologic Tumors Sarcoma Melanoma Myeloma Lung Ovarian Esophagogastric Breast Others NY-ESO-1 MAGE A-10 Head and neck Bladder Lung Breast Ovarian Melanoma Cervical Uterine Others AFP AFP Hepatocellular carcinoma / hepatoma AFP 12 other targets in research
Slide 13: Industry Leading TCR Pipeline: NY-ESO Development Program
Indication Research Pre-IND Phase 1/2 GSK option to license Industry Leading TCR Pipeline in Solid and Hematologic Cancers Comprehensive Development Program for NY-ESO T-cell Therapy Cohort 1: High NY-ESO expression, 12 patients Esophageal Synovial Sarcoma Cohort 2: Low NY-ESO expression, 10 patient
Slide 14: Industry Leading TCR Pipeline: Wholly-owned Targets
MAGE-A10 TCR Indication Research Pre-IND Phase 1/2 Industry Leading TCR Pipeline in Solid and Hematologic Cancers Deepest Pipeline of Wholly-owned Targets IND open Non-small cell lung cancer (NSCLC) Basket study: Solid tumors Safety testing ongoing; IND planned 1H16 Hepatocellular cancer Synovial Sa
Slide 15: Industry Leading TCR Pipeline in Solid and Hematologic Cancers
Industry Leading TCR Pipeline in Solid and Hematologic Cancers Deepest Pipeline of Wholly-owned Targets a mace-AtoTcr [i small cell lung cancer (N IND open Initiation Q4 2015 Basket study: Solid tumors > Enrollment in 2016 Generation 2 IND 2017 GRAMM Hepatocellular cancer Safety testing ongoing; IND
Slide 16: World Class Clinical Sites
World Class Clinical Sites Cityor The Children’s Hospital Hope. of Philadelphia” & UNIVERSITY OF MARYLAND PARK ‘Penn (CER INSTTUTE Yale Universi #3 Washington aleUniversiy J MOFEITE@D Thveyingion TIONAR Moa Santen CER INSTITUTE EW /A 2 Adaptimmune 16
Slide 17: ADAP Phase I/II Study in Synovial Sarcoma: Response Rates, Tolerability and Persistence
ADAP Phase I/II Study in Synovial Sarcoma Encouraging Response Rates, Tolerability and Persistence 60% response rate in the 10 patients who received target cell dose (at least 1x109 NY-ESO-1C259T cells) 50% overall response rate (6/12) in patients receiving any dose of cells 75% (9/12) of all patien
Slide 18: Synovial Sarcoma: Radiographic Pseudoprogression and Response of Lung Metastases
ADAP Phase I/II Study in Synovial Sarcoma Radiographic Pseudoprogression and Response of Lung Metastases Baseline: Bilateral Miliary Metastatic disease Day +2: Pseudoprogression due to Immune Infilration Day +101: Complete Response Patient 201 NY-ESO C-Reactive Protein AACR April 2015
Slide 19: Synovial Sarcoma: The Power of T-cell Therapy
NY-ESO TCR T cells administered ADAP Phase I/II Study in Synovial Sarcoma The Power of T-cell Therapy One month post NY-ESO TCR T cells Two months post NY-ESO T cells Source: Merchant, CTOS, 2014 ~ 70% reduction in lesion size at 2 months after administration of NY-ESO T-cells The lesion was then de
Slide 20: ADAP Phase I/II Study in Multiple Myeloma
ADAP Phase I/II Study in Multiple Myeloma Compelling Response Rate Compared to Published Literature Two year overall survival (OS) and progression free survival (PFS) as of November 2015 16/25 patients remain alive; 8/25 remain in remission Median PFS = 19.1 months Median OS = 32.1 months Response r
Slide 21: Recent Progress: Allogeneic program Universal Cells
Recent Progress: Allogeneic program Universal Cells
Slide 22: Enhanced Affinity Allogeneic T-cell Therapy
Enhanced Affinity Allogeneic T-cell Therapy Iterative, rAAV-based gene editing to: remove HLA Class I, II, TCR; Add HLA-X, high affinity TCR Long-term large-scale supply with COGS reduction 3-5 year project Differentiation into mature T-cells Enhanced Affinity Universal Donor Cell Multiple off-the-s
Slide 23: Universal Cells Agreement
Universal Cells Agreement Creating universal donor cells Exclusive Research and Collaboration Agreement for development of allogeneic T-cell therapies Potentially decreases cost of manufacture Enables large numbers of patients to be treated from the same manufacturing batch Universal Cells technolog
Slide 24: Universal Cells Agreement
Universal Cells Agreement Creating universal donor cells ™ Exclusive Research and Collaboration Agreement for development of allogeneic T-cell therapies = Potentially decreases cost of manufacture ™ Enables large numbers of patients to be treated from the same manufacturing batch ™ Universal Cells t
Slide 25: Large un-partnered pipeline with ability to target almost all major tumors
Large un-partnered pipeline with ability to target almost all major tumors Adaptimmune GSK 20+ Additional validated targets Twelve new targets selected for development Not yet nominated; programs with work ongoing are excluded Pool of 3: ADAP keeps 2 NY-ESO MAGE-A10 AFP 30+ validated therapeutic tar
Slide 26: 2015: Execution on All Fronts
2015: Execution on All Fronts Q1 2015 Additions to Adaptimmune senior leadership team April 2015 AACR presented full cohort data for NY-ESO in Sarcoma and MM May 2015 IPO raises $176m net proceeds Q2 2015 Filing and acceptance of IND for Phase 1/2 studies for MAGE A-10 Q3 2015 Publication of Nature
Slide 27: 2016: Continued Momentum and Evolution
2016: Continued Momentum and Evolution Multiple Candidates in Clinical Development for 9 indications Sarcoma Ovarian Lung Melanoma Myeloma 2016 File IND for AFP 2016 Expansion beyond oncology 2016 Additional Phase 1/2 data from NY-ESO clinical studies in: 2H 16 Initiate AFP study in hepatocellular c
Slide 28: Turning Promise into Products: Leading the TCR T-cell Therapy Space
Turning Promise into Products Leading the TCR T-cell Therapy Space A broad pipeline of clinical T-cell therapies to treat cancer First three programs target: NY-ESO First cohort in synovial sarcoma (solid tumor) shows 60% response rate at target dose First cohort in multiple myeloma (hematologic tum
Slide 29: Adaptimmune Transforming T-cell Therapy
Adaptimmune Transforming T-cell Therapy Presentation Materials December 2015
Slide 30: Adaptimmune Transforming T-cell Therapy
Adaptimmune Transforming T-cell Therapy Presentation Materials December 2015 BY Adaptimmune
Adaptimmune Therapeutics — Investor Presentation (December 2015) on 6ix